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nostic work-up of NSCLC patients’ leads to a reduction
of invasive procedures, resulting in cost savings of $669
per patient.
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OBJECTIVES: This study estimates the total health care
costs of ﬁve chemotherapeutic agents used to treat non-
small cell lung cancer (NSCLC) in Poland. This informa-
tion can be used to determine the most cost-efﬁcient
treatment option for health care providers in Poland.
METHODS: Two economic evaluations comparing 
gemcitabine/cisplatin (Gem/Cis) with four other novel
regimens were conducted using evidence from relevant
randomised controlled trials. The economic evaluation
based on the trial by Comella et al. (2000) compares
Gem/Cis with vinorelbine/cisplatin (Vin/Cis), while the
economic evaluation based on the trial by Schiller et al.
(2002) compares Gem/Cis with paclitaxel/cisplatin
(Pac/Cis), paclitaxel/carboplatin (Pac/Car), and doc-
etaxel/cisplatin (Doc/Cis). RESULTS: The economic eval-
uation based on the Comella et al. trial indicates that the
Gem/Cis combination is virtually cost neutral compared
to the Vin/Cis combination, costing an average of PLN
110 (€25) more per patient. The higher acquisition costs
of gemcitabine compared to vinorelbine were offset by
lower drug administration costs and lower rates of hos-
pitalisation for Gem/Cis patients. The economic evalua-
tion based on the Schiller et al. (2002) trial showed that
patients treated with Gem/Cis incurred higher total treat-
ment costs than those treated with Pac/Cis, by an average
of PLN 2880 (€652) per patient. However, patients
treated with Gem/Cis incurred signiﬁcantly lower total
treatment costs than those treated with Pac/Car and
Doc/Cis. The average cost savings associated with
Gem/Cis were PLN 1829 (€414) per patient and PLN
3921 (€888) per patient, respectively. CONCLUSIONS:
In Poland, Gem/Cis is the most advantageous treatment
alternative based on cost-minimisation for two out of 
the four comparators (Pac/Car and Doc/Cis). Using a
cost-effectiveness analysis, Gem/Cis is considered cost-
effective against the other two comparators (Vin/Cis 
and Pac/Cis). Overall, a claim for cost-effectiveness of
Gem/Cis regimens in the treatment of advanced NSCLC
is supported.
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OBJECTIVES: Complexed Prostate Speciﬁc Antigen
(cPSA) testing offers an improved speciﬁcity compared to
currently applied total PSA (tPSA) in the diagnosis of
prostate cancer in patients at risk. Our objective was to
assess the cost of cPSA if it would replace tPSA as ﬁrst
diagnostic test, based on medical management and cost
data for Belgium. Both tests have the same unit cost.
METHODS: A medical decision tree simulating a
patient’s ﬂow and applying a time horizon of one year
was developed in MS-Excel. Sensitivity and speciﬁcity
data were obtained from published directly comparative
clinical literature. An expert panel with 19 members (7
urologists and 12 general practioners) provided input
data regarding the further diagnostic work-up in case of
a positive PSA test and further therapeutical decisions and
medical resource use in relation to the diagnostic out-
comes (true and false positives and negatives). Costs of
medical resources were obtained from the public health
insurance perspective. RESULTS: When aiming for a
target sensitivity of 90%, a diagnosis starting with cPSA
costs €86.65 in total compared to €91.61 for tPSA. In a
second analysis, if published manufacturer cut-off values
were applied rather than a target sensitivity, total costs
were €75.50 and €91.60 respectively. The savings were
respectively €4.95 and €16.10 in favour of cPSA per
patient. For a yearly cohort of 500,000 men, savings up
to €8Mln could be realised. Sensitivity analyses on preva-
lence of prostate cancer and costs of diagnostic work-up
showed that the results were robust (savings range
€4.45–€5.46 in ﬁrst analysis and €13.3–€18.8 in second).
CONCLUSIONS: cPSA as standard screening test in
prostate cancer in patients at risk appears to have a strong
saving potential compared to the current use of tPSA.
Further research should focus on the psychological
impact of less false positive results.
CANCER—Quality of Life
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OBJECTIVE: To evaluate patient preference and Quality
of Life (QoL) with the administration of ﬁlgrastim versus
pegﬁlgrastim during myelosuppressive chemotherapy.
METHODS: Nine centres in France and 2 in Portugal
participated. The study was designed as an open-label,
cross-over trial with 76 cancer patients receiving 3 to 6
cycles of chemotherapy. Subjects were randomised on a 
1 :1 ratio to receive either multiple ﬁlgrastim injections
per cycle or pegﬁlgrastim as a single, ﬁxed-dose injection
once per cycle. In cycle 2, patients received the other study
medication. On day 1 of cycle 3, they were asked to com-
plete the Subject Preference Questionnaire to indicate
their preference for the remainder of the cycles. Data
